The Liquid Biopsy Movement: From MSK to the World

What began at our inaugural forum in 2024 has since taken shape across the field. SOPHiA GENETICS and the Memorial Sloan Kettering Cancer Center (MSK) return to ASCO to convene leading voices in precision oncology, this time with a singular focus: the liquid biopsy revolution.

This forum traces the journey from a pioneering academic-industry collaboration with MSK to a global movement reshaping how cancer is detected, monitored, and treated.

Topics:

From One Lab to the World: Liquid Biopsy as a Leapfrog Technology
The Power of the Network in Expanding Access to Advanced NGS LBx
Strategic Partnerships: The Engine Drivers
Leading Advances In Precision Oncology With Open Innovation

Speakers:

Bob T. Li, MD, PhD, MPH – Senior Vice President, Global Head of Medical Affairs, Oncology, AstraZeneca
Pedram Razavi, MD, PhD – Director, Liquid Biopsy and Cancer Genomics & MSK Biomarker Development Program, Memorial Sloan Kettering Cancer Center
Kojo Elenitoba-Johnson, MD – Chair of the Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center
Dale Muzzey – Chief Scientific Officer, Myriad Genetics
John Longshore, PhD, FACMG – Head of Scientific Affairs Global Oncology Diagnostics, AstraZeneca
Nicola Normanno, MD – Scientific Director, IRCCS Istituto Romagnolo per lo Studio dei Tumori “Dino Amadori”
Lou Welebob – Senior Vice President of BioPharma Companion Diagnostics, Myriad Genetics
Ross Muken – President, SOPHiA GENETICS
Philippe Menu, MD, PhD – EVP, Chief Medical Officer and Chief Product Officer, SOPHiA GENETICS
Jess Lambe - Vice President & Managing Director, BioPharma Business Development, SOPHiA

Watch Webinar

Facebook

This field is for validation purposes and should be left unchanged.

First Name(Required)

Last Name(Required)

Institution(Required)

Job Title(Required)

Area of Interest(Required)

Email(Required)

Phone

Country(Required)

Select US State(Required)

Privacy Policy(Required)

By checking this box, I declare that I have read and accepted in full SOPHiA GENETICS privacy policy. The data provided herein is used to process your request. Click here for more information relating to our privacy policy

Marketing Opt-In

I agree to receive information from SOPHiA GENETICS about products, services, events and promotions. I understand I will be able unsubscribe by using the link integrated with the communication at any time.

3rd Party Opt-In

I agree that SOPHiA GENETICS may share my webinar registration details with 3rd parties, and that I may receive marketing communications from these 3rd parties. I understand that I can withdraw my consent at any time.

This field is hidden when viewing the form

Job Title/Industry(Required)

CAPTCHA

Disclaimer notice:
The term SOPHIA used by the speaker refers to SOPHiA GENETICS and its products.
The opinions expressed during this presentation are those of the speakers and may not represent the opinions of SOPHiA GENETICS.
SOPHiA GENETICS does not provide support in the validation of custom products for clinical use.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.

SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.

SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.

All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.

SOPHiA DDM™ Overview

SOPHiA DDM™ for Genomics

SOPHiA DDM™ for Radiomics

SOPHiA DDM™ for Multimodal

Professional Services